This week’s Medicare updates include a proposed decision memo on coverage for CAR T-Cell therapy, an updated OIG work plan, the announcement of a new emergency services payment model, and more!
CMS is seeking comments on a proposed coverage with evidence development for chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory cancer when prescribed by the treating oncologist.
A financial assessment may be time-consuming and difficult, as many patients are reluctant to inform the case manager of the financial risks they face, but it is critical to assisting patients meet the most basic of needs.
